Exact Sciences Corp SEC Filings

Exact Sciences Corp. executive James Herriott, SVP, General Counsel & Secretary, reported selling 1,000 shares of the company’s common stock on 11/19/2025 at a price of $70 per share under a pre-arranged Rule 10b5-1 trading plan entered into on March 3, 2025. After this sale, he beneficially owns 11,585 shares directly and 1,556 shares held in a 401(k) plan, for a total of 13,141 shares. In addition, he holds an aggregate of 37,434 vested and unvested stock options and restricted stock units, each unit representing the right to receive one share of common stock.

Exact Sciences Corporation agreed to be acquired by Abbott Laboratories in an all-cash merger. Each share of Exact common stock will be converted at closing into the right to receive $105.00 in cash, subject to the terms and conditions of the merger agreement. Exact’s board of directors unanimously approved the deal and plans to recommend that stockholders adopt the merger agreement.

The transaction must be approved by a majority of Exact’s outstanding shares and obtain required antitrust and other regulatory clearances, with no law or order prohibiting completion. The merger agreement includes customary covenants restricting Exact’s ability to seek alternative transactions and requires Exact to operate in the ordinary course until closing. Either side can terminate under specified circumstances, including if the merger is not completed by November 19, 2026, and Exact may owe Abbott a termination fee of $628,694,446 in certain situations, such as accepting a superior proposal.

Exact Sciences (EXAS) executive James Herriott, SVP, General Counsel & Secretary, reported the sale of 1,500 shares of common stock at $70.08 on 11/04/2025. The transaction was made under a Rule 10b5-1 trading plan entered on March 3, 2025.

After the sale, Herriott beneficially owned 12,585 shares directly and 1,556 shares held indirectly in a 401(k) plan. He also holds an aggregate 37,434 vested and unvested options and restricted stock units.

Exact Sciences (EXAS) reported an insider transaction by EVP, GM, Precision Oncology Brian Baranick. He sold 2,858 shares of common stock on 11/04/2025 at $70.08 per share, executed pursuant to a Rule 10b5-1 trading plan entered into on May 13, 2024.

Following the sale, he beneficially owned 22,368 shares directly and 670 shares held in a 401(k) plan. In addition, he holds an aggregate of 73,080 vested and unvested options and restricted stock units, with each RSU representing a contingent right to receive one share of common stock.

Exact Sciences (EXAS) filed its quarterly report showing higher revenue and a narrower loss. Revenue for the quarter reached $850.739 million, up from $708.655 million a year ago, driven by both Screening and Precision Oncology. Net loss improved to $19.594 million from $38.236 million. Gross profit was $583.929 million.

By segment, Screening generated $666.240 million, while Precision Oncology contributed $184.499 million. For the first nine months, operating cash flow was $339.749 million, reflecting stronger collections and working capital. The company ended the quarter with $789.037 million in cash and cash equivalents and $214.058 million in marketable securities, totaling $1,003.095 million.

Convertible debt consisted of four series with a net carrying amount of $2.325 billion, and the company settled $249.172 million of 2025 notes in cash earlier in the year. Stockholders’ equity stood at $2.501 billion. Shares outstanding were 189,452,459 as of September 30, 2025; this is a baseline figure, not the amount being offered.

Exact Sciences Corporation announced its financial results for the quarter ended September 30, 2025, and furnished the related press release as Exhibit 99.1.

The information in this report and Exhibit 99.1 is being furnished, not filed, under Item 2.02 of Form 8-K. Item 9.01 lists the exhibits, including Exhibit 99.1 and the Inline XBRL cover page labeled as Exhibit 104.

Exact Sciences (EXAS) reported an insider transaction: a director sold shares in an open-market trade. On 10/24/2025, the reporting person sold 12,000 shares of common stock at $65 per share under a pre-arranged Rule 10b5-1 trading plan entered on 11/25/2024. Following the sale, the individual beneficially owns 60,759 shares, held directly.

Insider transaction summary: An officer of Exact Sciences Corporation sold 1,500 shares of common stock on 10/09/2025 at a price of $60 per share, leaving beneficial ownership of 14,085 shares reported on this form. The sale was executed under a written Rule 10b5-1 trading plan entered into on 03/03/2025, which the filer checked as applicable. In addition to the reported shares, the reporting person holds an aggregate 37,434 vested and unvested equity awards (options and restricted stock units), each restricted stock unit representing a contingent right to one share. The Form 4 was signed by an attorney-in-fact on 10/10/2025.

Director sale under 10b5-1 plan: A director of Exact Sciences Corp. (EXAS) sold 2,000 shares of common stock on 10/09/2025 at a price of $60 per share under a Rule 10b5-1 trading plan established on 03/09/2025. After the transaction the reporting person beneficially owned 57,962 shares. The sale was reported on a Form 4 executed by an attorney-in-fact. This filing discloses a single routine disposition by an insider using a pre-established plan and does not include other derivative or non-derivative transactions.